Literature DB >> 10768298

Topiramate as an inhibitor of carbonic anhydrase isoenzymes.

S J Dodgson1, R P Shank, B E Maryanoff.   

Abstract

PURPOSE: This study investigated the effectiveness of topiramate (TPM) as an inhibitor of six isozymes of carbonic anhydrase (CA).
METHODS: The inhibition constants (Ki) of TPM and acetazolamide (AZM) for CA I, CA II, CA III, CA IV, CA V, and CA VI were determined for human (HCA), rat (RCA), or mouse (MCA). The activity of CA was studied by using purified isozymes, erythrocytes, subcellular fractions of kidney or brain, and saliva, and was assayed at 37 degrees C or 25 degrees C by 18O mass spectrometry and/or by measuring the pH shift at 0 degrees C.
RESULTS: Topiramate Ki values for HCA I, HCA II, HCA IV, and HCA VI were approximately 100, 7, 10, and >100 microM, respectively. TPM Ki values for RCA I, RCA II, RCA III, RCA IV, and RCA V were approximately 180, 0.1 to 1, >100, 0.2 to 10 and 18 microM, respectively. For RCA II and RCA IV, the Ki values were temperature dependent. TPM Ki values for MCA II and MCA IV ranged between 1 and 20 microM.
CONCLUSIONS: These results indicate that TPM is more potent as an inhibitor of CA II and CA IV than of CA I, CA III, and CA VI. In all three species, AZM was usually 10 to 100 times more potent than TPM as an inhibitor of CA isozymes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768298     DOI: 10.1111/j.1528-1157.2000.tb06047.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  61 in total

Review 1.  Sinus venous stenosis, intracranial hypertension and progression of primary headaches.

Authors:  Roberto De Simone; Angelo Ranieri; Silvana Montella; Mario Marchese; Pasquale Persico; Vincenzo Bonavita
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

Review 2.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Hypothalamic regulatory pathways and potential obesity treatment targets.

Authors:  Erin E Jobst; Pablo J Enriori; Puspha Sinnayah; Michael A Cowley
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

4.  Crystal structure of human carbonic anhydrase II complexed with an anti-convulsant sugar sulphamate.

Authors:  Rosario Recacha; Michael J Costanzo; Bruce E Maryanoff; Debasish Chattopadhyay
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

5.  Carbonic anhydrase inhibition by acetazolamide reduces in vitro epileptiform synchronization.

Authors:  Shabnam Hamidi; Massimo Avoli
Journal:  Neuropharmacology       Date:  2015-04-29       Impact factor: 5.250

Review 6.  Is idiopathic intracranial hypertension without papilledema a risk factor for migraine progression?

Authors:  Roberto De Simone; Angelo Ranieri; Chiara Fiorillo; Leonilda Bilo; Vincenzo Bonavita
Journal:  Neurol Sci       Date:  2010-02-25       Impact factor: 3.307

Review 7.  Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders.

Authors:  Michael J Marmura; Aliza S Kumpinsky
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

8.  Enteral topiramate in a pediatric patient with refractory status epilepticus: a case report and review of the literature.

Authors:  Chasity M Shelton; Elizabeth L Alford; Stephanie Storgion; James Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec

Review 9.  Review of topiramate for the treatment of epilepsy in elderly patients.

Authors:  B R Sommer; H H Fenn
Journal:  Clin Interv Aging       Date:  2010-04-26       Impact factor: 4.458

10.  Topiramate in the treatment of partial and generalized epilepsy.

Authors:  Edward Faught
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.